1,372 research outputs found
Multidrug Resistance Studies in Patients with Acute Myeloid Leukemia
In the bone marrow, a continuous, strictly organized process of blood cell production or
hematopoiesis takes place. The human hematopoietic system is capable of replacing the
normal daily turnover of blood cells and is capable of maintaining a balance between the
blood cell formation and increased blood cell demands such as in bleeding or infection.
The different types of cells that are normally present in the peripheral blood are all
derived from committed progenitor cells. The comparttnent of these committed
progenitor cells is maintained by a small number of pluripotent stem cells. The
process of proliferation and differentiation is regulated by cellular interaction, the microenvironment
of the bone marrow, several regulatory glycoproteins and hematopoietic
growth factors.
Leukemia is the condition of malignant transfonnation of hematopoietic cells leading to
the accumulation of immature abnonnal cells in blood and bone marrow. According to
the clinical presentation, the leukemias are divided in acute and chronic leukemias.
Depending on the cell1ineage involved, a further distinction can be made in myeloid and
lymphoid leukemias. The focus of this thesis is on "acute myeloid leukemia" (AML).
AML is a clonal disease, characterized by a maturation arrest during the differentiation of
the hematopoietic cells to mature blood cells, leading to accumulation of a
population of immature abnormal myeloid cells, ultimately resulting in suppression of
normal hematopoeisis. Clinically, the replacement of normal functional blood cells by
leukemic blasts in bone marrow and peripheral blood will result in anemia,
granulocytopenia and thrombocytopenia
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia
Attempts to overcome multi-drug resistance in acute myeloid leukaemia (AML) have been limited by toxicities. To investigate the effect of reducing peak drug levels, we performed sequential phase II studies using continuous infusion daunorubicin and cytarabine without (AD) and then with ciclosporin (ADC) in older patients with AML. Untreated patients (age 56+ years) received daunorubicin (45 mg/m 2 per day for 3 d) and cytarabine (200 mg/m 2 per day for 7 d), both by continuous infusion, without (S0112, 60 patients) and then with (S0301, 50 patients) the addition of ciclosporin. Complete response (CR) rates were 38% on S0112 and 44% on S0301. Fatal induction toxicities occurred in 17% and 12% respectively, arising primarily from infection and haemorrhage. Median overall and relapse-free survival was 7 and 8 months for AD respectively, and 6 and 14 months for ADC. Patients with phenotypic or functional P-glycoprotein had somewhat higher CR rates with ADC than AD, although confidence intervals overlapped. In these sequential trials, continuous infusion AD produced CR rates comparable to those with bolus daunorubicin. The addition of ciclosporin did not cause undue toxicities, produced a similar CR rate, and possibly improved relapse-free survival. Further correlate analyses did not identify a subpopulation specifically benefitting from the addition of ciclosporin.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/78683/1/j.1365-2141.2009.07919.x.pd
Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only
Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia
Coagulation alterations may be involved in osteonecrosis in childhood acute lymphoblastic leukemia. Retrospectively, we evaluated the available coagulation parameters at diagnosis and during induction treatment of 161 acute lymphoblastic leukemia patients: 24 with symptomatic osteonecrosis (median age: 13.8 years, range 4.0-17.2) and 137 without osteonecrosis (median age: 4.9 years, range 1.0-16.7). Coagulation parameters of both groups were similar at diagnosis. After four weeks of treatment including dexamethasone, levels of antithrombin and protein S were significantly less in osteonecrosis-positive than in osteonecrosis-negative patients. Subsequently, after four doses of asparaginase and tapering dexamethasone, these coagulation parameters equally decreased in both groups. Consequently, nadirs of antithrombin and protein S were significantly lower in osteonecrosis-positive than in osteonecrosis- negative patients, even reaching levels below lower normal limits in the osteonecrosis-positive group. A reduced dexamethasone related increase of antithrombin and protein S, and subsequent decline below normal levels after introduction of asparaginase, may result in a hypercoagulable state, contributing to development of symptomatic osteonecrosis
Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia
Subtype prediction in pediatric acute myeloid leukemia: Classification using differential network rank conservation revisited
Background: One of the most important application spectrums of transcriptomic data is cancer phenotype classification. Many characteristics of transcriptomic data, such as redundant features and technical artifacts, make over-fitting commonplace. Promising classification results often fail to generalize across datasets with different sources, platforms, or preprocessing. Recently a novel differential network rank conservation (DIRAC) algorithm to characterize cancer phenotypes using transcriptomic data. DIRAC is a member of a family of algorithms that have shown useful for disease classification based on the relative expression of genes. Combining the robustness of this family's simple decision rules with known biological relationships, this systems approach identifies interpretable, yet highly discriminate networks. While DIRAC has been briefly employed for several classification problems in the original paper, the potentials of DIRAC in cancer phenotype classification, and especially robustness against artifacts in transcriptomic data have not been fully characterized yet. Results: In this study we thoroughly investigate the potentials of DIRAC by applying it to multiple datasets, and examine the variations in classification performances when datasets are (i) treated and untreated for batch effect; (ii) preprocessed with different techniques. We also propose the first DIRAC-based classifier to integrate multiple networks. We show that the DIRAC-based classifier is very robust in the examined scenarios. To our surprise, the trained DIRAC-based classifier even translated well to a dataset with different biological characteristics in the presence of substantial batch effects that, as shown here, plagued the standard expression value based classifier. In addition, the DIRAC-based classifier, because of the integrated biological information, also suggests pathways to target in specific subtypes, which may enhance the establishment of personalized therapy in diseases such as pediatric AML. In order to better comprehend the prediction power of the DIRAC-based classifier in general, we also performed classifications using publicly available datasets from breast and lung cancer. Furthermore, multiple well-known classification algorithms were utilized to create an ideal test bed for comparing the DIRAC-based classifier with the standard gene expression value based classifier. We observed that the DIRAC-based classifier greatly outperforms its rival. Conclusions: Based on our experiments with multiple datasets, we propose that DIRAC is a promising solution to the lack of generalizability in classification efforts that uses transcriptomic data. We believe that superior performances presented in this study may motivate other to initiate a new aline of research to explore the untapped power of DIRAC in a broad range of cancer types
11q23 rearrangements in de novo childhood acute myeloid leukemia
Review on 11q23 rearrangements in de novo childhood acute myeloid leukemia, with data on clinics, and the genes involved
- …